In October 2020, the tremelimumab (a CTLA-4 inhibitor) plus durvalumab (a PD-L1 inhibitor) regimen was the first combination immunotherapy with anti-PD-L1 and anti-CTLA-4 antibodies approved for the treatment of adult patients with unresectable HCC 45. The gene discussed is CTLA4; the disease is hepatocellular carcinoma.